|
Books > Business & Economics > Industry & industrial studies > Manufacturing industries > Pharmaceutical industries
This searing indictment, David HealyOCOs most comprehensive and
forceful argument against the pharmaceuticalization of medicine,
tackles problems in health care that are leading to a growing
number of deaths and disabilities. Healy, who was the first to draw
attention to the now well-publicized suicide-inducing side effects
of many anti-depressants, attributes our current state of affairs
to three key factors: product rather than process patents on drugs,
the classification of certain drugs as prescription-only, and
industry-controlled drug trials. These developments have tied the
survival of pharmaceutical companies to the development of
blockbuster drugs, so that they must overhype benefits and deny
real hazards. Healy further explains why these trends have
basically ended the possibility of universal health care in the
United States and elsewhere around the world. He concludes with
suggestions for reform of our currently corrupted evidence-based
medical system.
The period from the late seventeenth to the early nineteenth
century-the so-called long eighteenth century of English
history-was a time of profound global change, marked by the
expansion of intercontinental empires, long-distance trade, and
human enslavement. It was also the moment when medicines,
previously produced locally and in small batches, became global
products. As greater numbers of British subjects struggled to
survive overseas, more medicines than ever were manufactured and
exported to help them. Most historical accounts, however, obscure
the medicine trade's dependence on slave labor, plantation
agriculture, and colonial warfare. In Merchants of Medicines,
Zachary Dorner follows the earliest industrial pharmaceuticals from
their manufacture in the United Kingdom, across trade routes, and
to the edges of empire, telling a story of what medicines were,
what they did, and what they meant. He brings to life business,
medical, and government records to evoke a vibrant early modern
world of London laboratories, Caribbean estates, South Asian
factories, New England timber camps, and ships at sea. In these
settings, medicines were produced, distributed, and consumed in new
ways to help confront challenges of distance, labor, and authority
in colonial territories. Merchants of Medicines offers a new
history of economic and medical development across early America,
Britain, and South Asia, revealing the unsettlingly close ties
among medicine, finance, warfare, and slavery that changed people's
expectations of their health and their bodies.
Gary Gereffi first explains how foreign corporations took over the
flourishing Mexican steroid industry in the 1950s and 1960s and
thwarted the country's later attempts to establish a more equitable
distribution of industry benefits. In this valuable theoretical
contribution Professor Gereffi uses the Mexican industry's plight
as a crucial-case test for dependency theory Originally published
in 1983. The Princeton Legacy Library uses the latest
print-on-demand technology to again make available previously
out-of-print books from the distinguished backlist of Princeton
University Press. These editions preserve the original texts of
these important books while presenting them in durable paperback
and hardcover editions. The goal of the Princeton Legacy Library is
to vastly increase access to the rich scholarly heritage found in
the thousands of books published by Princeton University Press
since its founding in 1905.
Despite the pharmaceutical industry's notable contributions to
human progress, including the development of miracle drugs for
treating cancer, AIDS, and heart disease, there is a growing
tension between the industry and the public. Debates are raging
over how the industry can and should be expected to act. In this
volume leading figures in industry, government, NGOs, the medical
community, and academia discuss and propose solutions to the
ethical dilemmas of drug industry behavior. They examine such
aspects as the role of intellectual property rights and patent
protection, the moral and economic requisites of research and
clinical trials, drug pricing, marketing and advertising. . Michael
Santoro is Associate Professor with tenure in the Business
Environment Department at Rutgers Business School, where he teaches
courses on business ethics, public policy, labor and human rights,
law, ethical issues in the pharmaceutical industry and China
business strategy. As a Research Associate at Harvard Business
School, he wrote or co-authored nearly thirty case studies and
teaching notes on ethical and legal topics such as global
protection of intellectual property, insider trading, the Federal
Sentencing Guidelines and Fair Credit Reporting Act. Thomas Gorrie
is Corporate Vice President, Government Affairs & Policy, at
Johnson & Johnson, with responsiblity for all federal, state
and international government affairs and policy. He completed
post-doctoral studies at the Swiss Federal Institute of Technology
in Zurich, following the receipt of his doctorate at Princeton
University. Gorrie has over 30 years of worldwide health care
experience and has worked with various Johnson & Johnson
companies inresearch and development, marketing and sales, business
development, strategic planning, general management, international,
venture capital, and health policy.
Experiments on patients, processes or plants all have random error,
making statistical methods essential for their efficient design and
analysis. This book presents the theory and methods of optimum
experimental design, making them available through the use of SAS
programs. Little previous statistical knowledge is assumed. The
first part of the book stresses the importance of models in the
analysis of data and introduces least squares fitting and simple
optimum experimental designs. The second part presents a more
detailed discussion of the general theory and of a wide variety of
experiments. The book stresses the use of SAS to provide hands-on
solutions for the construction of designs in both standard and
non-standard situations. The mathematical theory of the designs is
developed in parallel with their construction in SAS, so providing
motivation for the development of the subject. Many chapters cover
self-contained topics drawn from science, engineering and
pharmaceutical investigations, such as response surface designs,
blocking of experiments, designs for mixture experiments and for
nonlinear and generalized linear models. Understanding is aided by
the provision of "SAS tasks" after most chapters as well as by more
traditional exercises and a fully supported website. The authors
are leading experts in key fields and this book is ideal for
statisticians and scientists in academia, research and the process
and pharmaceutical industries.
Ernest Solvay, philanthropist and organizer of the world-famous
Solvay conferences on physics, discovered a profitable way of
making soda ash in 1861. Together with a handful of associates, he
laid the foundations of the Solvay company, which successfully
branched out to other chemicals, plastics, and pharmaceuticals.
Since its emergence in 1863, Solvay has maintained world leadership
in the production of soda ash. This is the first scholarly book on
the history of the Solvay company, which was one of the earliest
chemical multinationals and today is among the world's twenty
largest chemical companies. It is also one of the largest companies
in the field to preserve its family character. The authors analyze
the company's 150-year history (1863 2013) from economic,
political, and social perspectives, showing the enormous impact
geopolitical events had on the company and the recent consequences
of global competition."
Gary Gereffi first explains how foreign corporations took over the
flourishing Mexican steroid industry in the 1950s and 1960s and
thwarted the country's later attempts to establish a more equitable
distribution of industry benefits. In this valuable theoretical
contribution Professor Gereffi uses the Mexican industry's plight
as a crucial-case test for dependency theory Originally published
in 1983. The Princeton Legacy Library uses the latest
print-on-demand technology to again make available previously
out-of-print books from the distinguished backlist of Princeton
University Press. These editions preserve the original texts of
these important books while presenting them in durable paperback
and hardcover editions. The goal of the Princeton Legacy Library is
to vastly increase access to the rich scholarly heritage found in
the thousands of books published by Princeton University Press
since its founding in 1905.
Key Account Management Excellence in Pharma & Medtech is
designed to help life sciences practitioners develop and execute
innovative and effective key account management (KAM) strategies
and capabilities. Pharmaceutical and medtech companies are
increasingly pursuing KAM in response to the rapid rise of large,
sophisticated and complex healthcare provider and payer systems and
groups. Those that invest the time to get KAM right will protect
their business and grow with these rising customers. This book is
groundbreaking in both its scope and its tailoring of leading KAM
practices specifically for life sciences. The central theme is that
"key account management is an organization-wide business strategy,
not just a role or a sales-specific initiative." KAM is a strategy
focused on providing unique offerings and value through an
orchestrated, cross-functional, go-to-market model designed
specifically to address the needs and engagement preferences of a
unique segment of customers. The insights and practices shared in
this book are designed to be a valuable reference at every stage of
the KAM journey. The book has been designed to facilitate a common
language and deep understanding of KAM issues and leading practices
organization-wide-particularly for life sciences leaders, account
managers and cross-functional team members responsible for
building, transforming and supporting their organization's KAM
strategies and capabilities.
The pharmaceutical industry is broken. From the American hedge fund
manager who hiked the price of an AIDS pill from $17.50 to $750
overnight to the children's cancer drugs left intentionally to
expire in a Spanish warehouse, the signs of this dysfunction are
all around. A system that was designed to drive innovation and
patient care has been relentlessly distorted to drive up profits.
Medicines have become nothing more than financial assets. The focus
of drug research, how drugs are priced and who has access to them
is now dictated by shareholder value, not the good of the public.
Drug companies fixated on ever-higher profits are being fined for
bribing doctors and striking secret price-gouging deals, while
patients desperate for life-saving medicines are driven to the
black market in search of drugs that national health services can't
afford. Sick Money argues that the way medicines are developed and
paid for is no longer working. Unless we take action we risk a
dramatic decline in the pace of drug development and a future in
which medicines are only available to the highest bidder. In this
book investigative journalist Billy Kenber offers a diagnosis of an
industry in crisis and a prescription for how we can fight back.
In pharmaceutical patent law, the problem of lack of policy
direction and inappropriate legal framework is widespread -
particularly among jurisdictions with little to no pharmaceutical
research or manufacturing. This book aims to inform public policy
and influence debate through a comprehensive review of Hong Kong's
pharmaceutical patent law. By demonstrating the need for a holistic
review of pharmaceutical patent laws and evaluating Hong Kong's
system in light of health policy, economic and social factors,
Bryan Mercurio recommends changes to the legal framework and
constructs a more efficient and effective system for Hong Kong. He
thoroughly evaluates the international framework and best practice
models to offer a global perspective to each issue before providing
local context in the analysis. While the focus of the book is Hong
Kong, the analysis on pharmaceutical patent law and policy extends
to other jurisdictions facing issues on reforming their national
system.
Photophysics and Nanophysics in Therapeutics explores the latest
advances and applications of phototherapy and nanotherapy, covering
the application of light, radiation, and nanotechnology in
therapeutics, along with the fundamental principles of physics in
these areas. Consisting of two parts, the book first features a
range of chapters covering phototherapeutics, from the fundamentals
of photodynamic therapy (PDT) to applications such as cancer
treatment and advances in radiotherapy, applied physics in cancer
radiotherapy treatment, and the role of carbon ion beam therapy.
Other sections cover nanotherapeutics, potential applications and
challenges, and nanotherapy for drug delivery to the brain. Final
chapters delve into nanotechnology in the diagnosis and treatment
of cancers, the role of nanocarriers for HIV treatment,
nanoparticles for rheumatoid arthritis treatment, peptide
functionalized nanomaterials as microbial sensors, and theranostic
nanoagents.
There is plenty of controversy surrounding pharmaceuticals, but it
cannot be denied that the pharmaceutical industry is both socially
beneficial and profitable. Regulators are expected to ensure that
the economic success of the industry does not come at the expense
of public safety, yet they have also assumed a cooperative role by
providing advice on regulation and by targeting unmet medical
needs. Concerns over regulatory standards, conflicts of interest,
and the manipulation of information on drug safety and
effectiveness have led to public mistrust and a greater need for
transparency between the pharmaceutical industry and government
regulators. Transparency, Power, and Influence in the
Pharmaceutical Industry evaluates the progress made in holding the
pharmaceutical industry responsible for creating transparency in
the industry, from development to market. The contributors to this
volume examine the various mechanisms introduced to make the
regulatory process more informative and situate these efforts
within the larger project of enhancing the safety of drugs,
vaccines, and other products.
"How do you market a successful brand in today's constantly
changing healthcare industry? Markus Saba and Hilary Gentile have
spent decades confronting that challenge. In Brand Plan Rx, they
show us how to use a simple and powerful framework of inspirational
storytelling." -Arianna Huffington, founder and CEO, Thrive Global
Build a healthcare brand that changes lives. A thriving brand
requires a plan. Even the best marketing ideas cannot come to
fruition without a cohesive brand plan. This is especially relevant
and challenging in the health and wellness industry. Brand Plan Rx
provides a proven road map that empowers you to make the choices
that drive demand and will get you to synthesize your plan onto one
page designed specifically with the health and wellness industry in
mind. In Brand Plan Rx, healthcare and pharmaceutical marketing
executives, professor Markus Saba and marketer Hilary Gentile,
provide a step-by-step formula to uncover the unique needs that
drive brand choice in the health and wellness industry. Drawing on
their decades of work in launching major pharmaceutical and
wellness brands, they outline exactly how you can create a strong,
effective brand plan to launch and market your brand. Brand Plan
Rx's Choice Map guides you through the difficult decisions that
will build your brand. You will bring it all together into a
cohesive and clear brand story. As you master synthesis and
clarity, you will create a one-page Cohesion Map, a clear roadmap
to use as your sounding board for all decisions you make for your
brand. Ultimately, you'll learn how to apply traditional marketing
principles to the healthcare space so that your brand will make a
marked difference in people's lives. "Captures the essence of brand
planning in the pharma/biotech space in a manner that is clear,
simple, and practical." -Enrique Conterno, CEO, FibroGen, Inc. "A
book that considers all the distinct factors of marketing in the
healthcare industry. Practical, to the point, entertaining, and
educational." -Rolf Hoffmann, chairman of the board of directors,
Biotest "I recommend this book to all commercial leaders in our
industry." -Burcu Eryilmaz, VP, Sanofi Genzyme "An essential guide
from industry experts who have spearheaded thousands of successful
launches." -Danielle Kayembe, founder and CEO, GreyFire Impact
|
|